Brian L. Wilson
Brian L. Wilson
Stop FollowingBrian L. Wilson
View as an RSS Feed
View Brian L. Wilson's Articles BY TICKER:
AAPL,
ABIO,
ABT,
ACAD,
ACHN,
ACRX,
AEGR,
AEZS,
AFFY,
ALXA,
AMPE,
AMRN,
AMZN,
ANAC,
ANTH,
APPA.OB,
APPY,
ARAY,
ARIA,
ARNA,
ARQL,
ARRY,
ASTX,
ATHX,
ATRS,
AVEO,
BAC,
BBRY,
BCRX,
BHP,
BIIB,
BLRX,
BMRN,
C,
CBMX,
CELG,
CHTP,
CLDX,
CLSN,
CORT,
CPRX,
CRME,
CUR,
CVM,
CYCC,
CYNO,
CYTK,
DARA,
DCTH,
DIS,
DMPI.OB,
DNDN,
DSCO,
DVAX,
EDAP,
EXEL,
F,
FOLD,
FRX,
FURX,
GALT,
GE,
GSK,
GWAY,
HALO,
HPTX,
HZNP,
IBM,
IMGN,
INO,
INTC,
ISIS,
ITMN,
JNJ,
JPM,
KERX,
KO,
LLY,
LNG,
LON,
LPTN,
LXRX,
MAKO,
MDVN,
MNKD,
MRK,
MSLP.OB,
MYRX,
NAVB,
NPSP,
NSPH,
NVS,
OMER,
ONCY,
ONXX,
OPXA,
ORCL,
OREX,
OSIR,
OSUR,
OXY,
PCRX,
PCYC,
PFE,
PGNX,
PPHM,
PTN,
QCOR,
REGN,
RIGL,
RMTI,
RPRX,
RPTP,
SCMP,
SDRL,
SGMO,
SKUL,
SLV,
SNGX.OB,
SPPI,
SPY,
SRPT,
STML,
STXS,
SUPN,
T,
THRX,
TKMR,
TLON.OB,
TTNP.OB,
VRTX,
VVUS,
WMT,
ZGNX,
ZIOP
- Dynavax Gets Crushed After Advisory Committee Vote
- Pessimism On Vertex Pharmaceuticals Increases, Erasing Previous Gains
- Palatin Investors Prepared For The Long Haul With Another FSD Drug
- Anthera's Lupus Drug Gets Second Chance After Clinical Trial Disaster
- Amarin Releases Q3 Results: What You Need To Know
- Biotech Weekend Recap: Important Developments And Big Releases
- For Biotech Investors: 5 Orphan Drugs And Their Parent Companies
- Vivus Reports A Weak 1st Quarter For Qsymia
- BioMarin Sees Major Rally On Phase III Orphan Drug
- BioCryst Erases Year's Gains On A Failed HCV Preclinical Program
- Amarin Stagnates On Frustrating M&A Speculation And (More) Waiting
- Clear Bullish Potential In Navidea's Future
- 3 November Catalysts For Biotech Traders
- How To Trade 'Stagnant Intel'
- Biotech Weekend Recap: Earnings Reports And Disappointments
- Redemption Still Possible For 2 Fallen Biotech Stocks
- Remaining Stereotaxis Investors Still Optimistic On Vdrive
- Gauging Cynosure's Intense Rally
- Putting Questcor's Counter-Rally Into Perspective
- Biotech Weekend Recap: Tug Of War
- Exelixis Stock Treads Water Ahead Of FDA Decision
- Bears Still Betting Strong Against Vivus, Arena And Orexigen
- Did Shares Of Isis Finally Bottom Out?
- Frustrating Trading Session For Sarepta
- Is Questcor's Recovery Rally Exhausted Yet?
- Biotech Weekend Recap: Bears, Bears Everywhere
- Processing Aegerion Pharmaceuticals' Recent Rally
- Delcath Systems: A Frustrating Stock With Quite A Bit Of Value Potential
- Cyclacel Heats Up On Clinical Trial Progression
- Trading Spectrum Pharmaceuticals - A Closer Look
- Biotech Weekend Recap: Clinical Trials, Company Files
- Clinical Trial Data Spikes Lexicon Pharma Shares
